TIBET PHARMA released its semi-annual performance report, with a net profit attributable to the parent company of 567 million yuan, a year-on-year decrease of 8.96%

According to the Zhitong Finance APP, TIBET PHARMA disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.651 billion yuan, a year-on-year increase of 2.23%; the net profit attributable to shareholders of the listed company was 567 million yuan, a year-on-year decrease of 8.96%; the net profit after deducting non-recurring gains and losses was 543 million yuan, a year-on-year increase of 3.69%; the basic earnings per share were 1.76 yuan. The company plans to distribute a cash dividend of 8.81 yuan (tax included) for every 10 shares to all shareholders